By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Sound Pharmaceuticals, Inc. 

4010 Stone Way, N Suite 120

Seattle  Washington  98103  U.S.A.
Phone: 206-634-2559 Fax: 206-634-2342



Company News
FDA Allows Sound Pharmaceuticals, Inc. To Begin Meniere's Disease Clinical Trial 1/5/2016 7:37:20 AM
Sound Pharmaceuticals, Inc. Submits Positive Phase 2 Clinical Trial Data On SPI-1005 For The Prevention And Treatment Of Sensorineural Hearing Loss 2/18/2014 7:09:50 AM
Sound Pharmaceuticals, Inc. Successfully Completes Its First Phase 2 Clinical Trial With SPI-1005 Involving iPod® or Noise Induced Hearing Loss 11/5/2013 9:43:00 AM
Sound Pharmaceuticals, Inc. Release: University of Florida Begins iPod® Trial With SPI-1005 to Prevent Hearing Loss 12/6/2012 10:18:58 AM
Nobel Prize Winner Bruce Beutler Joins Sound Pharmaceuticals, Inc. 11/29/2012 11:39:18 AM
Sound Pharmaceuticals, Inc. Announces a New SPI-1005 Clinical Trial Involving Personal Music Players 6/6/2011 10:27:24 AM
University of California, Los Angeles (UCLA) and Sound Pharmaceuticals, Inc. Identify a Key Hearing Regeneration Protein in the Human Inner Ear 2/25/2011 7:10:26 AM
Sound Pharmaceuticals, Inc. Receives an Office of Naval Research Award for Its Hearing Loss Research and Development 8/20/2009 7:46:45 AM
FDA Allows Phase 2 Study for Sound Pharmaceuticals, Inc.'s Novel Drug to Prevent Chemotherapy Induced Hearing Loss 8/8/2008 6:08:55 AM
Sound Pharmaceuticals, Inc. Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 7/24/2008 6:47:10 AM